BiotechTube

Apatinib

Phase 2UNKNOWN
0 views this week 0 watching💤 Quiet
Interest: 31/100
31
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Biliary Tract Cancer

Conditions

Biliary Tract Cancer

Trial Timeline

Feb 22, 2017 → Mar 1, 2019

NCT ID
NCT03144856

About Apatinib

Apatinib is a phase 2 stage product being developed by Jiangsu Hengrui Medicine for Biliary Tract Cancer. The current trial status is unknown. This product is registered under clinical trial identifier NCT03144856. Target conditions include Biliary Tract Cancer.

What happened to similar drugs?

2 of 20 similar drugs in Biliary Tract Cancer were approved

Approved (2) Terminated (0) Active (18)
✅Tranexamic acid + Standard of CarePfizerApproved
✅abataceptBristol Myers SquibbApproved
🔄Rilvegostomig + Durvalumab + Gemcitabine/CisplatinAstraZenecaPhase 3
🔄durvalumabAstraZenecaPhase 3
🔄Rilvegostomig + Placebo + Capecitabine + Gemcitabine/Cisplatin + S-1 [Tegafur/Oteracil/gimeracil]AstraZenecaPhase 3
🔄Gemcitabine + Cisplatin + Durvalumab + Trastuzumab deruxtecan + RilvegostomigAstraZenecaPhase 3
🔄Durvalumab + Gemcitabine monotherapy + Gemcitabine + cisplatin + Gemcitabine + oxaliplatin + Gemcitabine + carboplatin + Gemcitabine + cisplatin + S-1 + Gemcitabine + S-1 + Gemcitabine + cisplatin + albumin-bound paclitaxelAstraZenecaPhase 3

Hype Score Breakdown

Clinical
12
Activity
4
Company
15
Novelty
0
Community
0

Clinical Trials (20)

NCT IDPhaseStatus
NCT05029453ApprovedUNKNOWN
NCT03709953Phase 2UNKNOWN
NCT03457467Phase 2UNKNOWN
NCT03521219Phase 2UNKNOWN
NCT03390062Phase 2UNKNOWN
NCT03403452Phase 2UNKNOWN
NCT03383237Phase 2UNKNOWN
NCT03376737Phase 2UNKNOWN
NCT03251443Phase 2Completed
NCT03190616Phase 2Completed
NCT03163381Phase 2UNKNOWN
NCT03180476Phase 2Completed
NCT03144856Phase 2UNKNOWN
NCT03170310Phase 2UNKNOWN
NCT02764268Pre-clinicalCompleted
NCT02727309Phase 1/2UNKNOWN
NCT02509806Phase 2/3UNKNOWN
NCT02510469Phase 2/3UNKNOWN
NCT01653561Phase 2Completed
NCT01192971Phase 2Completed

Competing Products

20 competing products in Biliary Tract Cancer

See all competitors
ProductCompanyStageHype Score
mFOLFOX regimen + MitazalimabAlligator Bioscience ABPhase 2/3
35
Trastuzumab deruxtecanDaiichi SankyoPhase 2
39
Trastuzumab deruxtecanDaiichi SankyoPhase 2
42
Camrelizumab and Apatinib Plus GPSun PharmaceuticalPhase 1/2
28
Recaticimab and Adebrelimab + GP chemotherapySun PharmaceuticalPhase 2
42
Fenofibrate IDD-P (Insoluble Drug Delivery-Micro Particle)ShionogiPhase 2
35
E6011 + PlaceboEisaiPhase 2
27
LenvatinibEisaiPhase 2
35
gemcitabine + cisplatinEli LillyPhase 2
35
gemcitabine + cisplatinEli LillyPhase 2
35
Ramucirumab + Merestinib + Cisplatin + Gemcitabine + Placebo Oral + Placebo IVEli LillyPhase 2
39
Baricitinib + PlaceboEli LillyPhase 2
27
AbemaciclibEli LillyPhase 2
27
SHR-A1811Jiangsu Hengrui MedicinePhase 2
42
SHR1258Jiangsu Hengrui MedicinePhase 2
27
SHR-1210+GEMOXJiangsu Hengrui MedicinePhase 2
35
Rilvegostomig + Durvalumab + Gemcitabine/CisplatinAstraZenecaPhase 3
47
Durvalumab + Gemcitabine + CisplatinAstraZenecaPre-clinical
33
durvalumabAstraZenecaPhase 3
40
gemcitabine + cisplatin + Placebo + cisplatin + cediranib + gemcitabineAstraZenecaPhase 2/3
38